QI
BIVV

Quotient Investors’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Quotient Investors’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$420K Buy
+7,351
New +$431K 0.29% 99

Other funds holding BIVV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Quotient Investors's BIVV Position: Q3 2017 in Review

Quotient Investors opened a new position in Bioverativ Inc. Common Stock (BIVV) in Q3 2017: 7,351 shares worth $420K. The stake represents 0.29% of the portfolio and ranks #99 among its holdings.

446 funds tracked by Wall St. Rank hold BIVV as of Q3 2017.

  • Quotient Investors held 7,351 shares of Bioverativ Inc. Common Stock worth $420K as of Q3 2017.
  • Bioverativ Inc. Common Stock was a new Quotient Investors position in Q3 2017.
  • Bioverativ Inc. Common Stock made up 0.29% of Quotient Investors's portfolio in Q3 2017, its #99 holding.
  • 446 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q3 2017.

Based on Quotient Investors's 13F filing for Q3 2017, filed 18 Oct 2017.